Lirilumab

Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer.^[1][2] It binds to KIR2DL1/2/3.^[3]

Lirilumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	KIR2DL1/2/3
Clinical data
ATC code	none
Identifiers
CAS Number	1000676-41-4
ChemSpider	none
UNII	S9XDI9W918
KEGG	D10444
Chemical and physical data
Formula	C6452H9918N1698O2030S46
Molar mass	145228.93 g·mol−1

This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.

Clinical trials

A phase 2 clinical trial for acute myeloid leukemia (AML)^[4] was terminated early ("failed") in 2017.^[5]

It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN),^[6] but it may be abandoned.^[7]

As of November 2017^[update] nine clinical trials of lirilumab are registered as active.^[8]

References

1. World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
2. Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab, American Medical Association.
3. Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N (September 2009). "Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells". Blood. 114 (13): 2667–77. doi:10.1182/blood-2009-02-206532. PMC 2756126. PMID 19553639.
4. Clinical trial number NCT01687387 for "Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)" at ClinicalTrials.gov
5. Innate Pharma Leukemia Candidate Lirilumab Fails Phase II Trial. Feb 2017
6. Clinical trial number NCT03341936 for "Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck " at ClinicalTrials.gov
7. Bad news for Innate Pharma as BMS-backed drug stumbles nov 2017
8. lirilumab trials